MYC and gastric cancer: According to research, ARV-825 as the PROTAC drug effectively inhibits the growth of GC cells and elevates the apoptosis through downregulation of c-MYC and PLK1, suggesting that it may be a better therapeutic strategy for GC (158), while the clinical application of ARV-825 needs to explore continually.